Drugs / TINEFCON
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01373567 | Dec 2010 → Feb 2012 | psoriasis | Piramal Enterprises Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tinefcon | “Two 700 mg tablets of Tinefcon in the morning and evening to be taken orally.” NCT01373567 ↗ |
| Action | Inhibit | “novel oral TNF-alpha release inhibitor” NCT01373567 ↗ |
| Route | Oral | “taken orally” NCT01373567 ↗ |